Navigation Links
Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
Date:6/10/2008

COPENHAGEN, Denmark, June 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today a Phase I/II study to evaluate a subcutaneous route of administration of ofatumumab (HuMax-CD20(R)) in rheumatoid arthritis (RA) patients, stable on methotrexate will be initiated soon. The study, which will consist of two parts and include approximately 70 patients, will be conducted by GlaxoSmithKline.

"The addition of a subcutaneous method of administrating ofatumumab is a great addition to the ofatumumab development program. We hope this will in future prove to be an advantage to RA patients, who would potentially be able to administer ofatumumab on an outpatient basis," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Ofatumumab is an investigational drug being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma and rheumatoid arthritis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country.

About the trial This is a two part study. The objective of Part A of the study is to characterize the safety and tolerability of ofatumumab when administered subcutaneously. The primary endpoint is safety and tolerability. The primary endpoint for Part B is to characterize the pharmacokinetics/pharmacodynamics of subcutaneous dosing. Patients in both Part A and Part B are allowed to continue a stable dose methotrexate therapy.

Part A will be a randomized, single-blind, placebo controlled, repeat dose, parallel group, dose-range finding study of approximately 40 patients. Administration of ofatumumab for Part A will occur in a hospital based unit in order to ensure safety.

Part B will be a blinded, randomized, placebo controlled study. On the basis of findings in Part A of the study selected doses will be taken forward for administration in Part B. Dosing for Part B is planned to be conducted
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genmab Announces Updates on Phase III Cancer Studies
2. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
3. Bionomics Achieves US$1 Million Milestone Payment from Genmab
4. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
5. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
6. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
9. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
10. Maine Natural Health Company Conducts Dental Clinical Trial
11. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 Scott Steiger ... most of the world. As an engineer for the past 20 ... member of the military service. He,s been to six of the ... Photo - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... for travelers, he has a pretty good idea of what,s required. ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... at a rate of 4%, with world market ... Kalorama Information. MRI and other types of medical ... and treatment of numerous medical conditions in children ... and techniques. Kalorama,s report, Medical Imaging Markets ...
Breaking Medicine Technology:Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... , , SEATTLE, Dec. 9 Omeros Corporation today ... to serve on the Company,s Board. Mr. Spiegelman has also been ... are very pleased to welcome Dan to our Board and look ... CEO of Omeros. "Dan brings a substantial depth and breadth of ...
... , WALTHAM, Mass., Dec. 9 Decision ... focusing on pharmaceutical and healthcare issues, finds that compared to ... are being used more often to treat newly diagnosed patients ... second-line patients received a TNF-alpha inhibitor versus one year ago ...
Cached Medicine Technology:Daniel K. Spiegelman Elected to Board of Directors of Omeros 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3
(Date:11/28/2014)... Recently, BellasDress , a renowned dress manufacturer in the ... of cocktail dresses. In addition, these fresh dresses are available ... shipping on orders over $179. The aim of the special ... providing many styles of dresses, which come in various colors; ... more. All of them are on sale at affordable prices. ...
(Date:11/28/2014)... November 29, 2014 Recently, SWAccessControl.com, a ... systems. At the moment, all these high end products ... off. The special offer will last from today to ... “We are happy to launch the promotion. We are ... worldwide distributors with the latest information about our hottest ...
(Date:11/28/2014)... Recently, PrettyTailor.com has developed and created its new collection ... world in celebration of the coming holiday season. To ... special offer on all these outfits. Click here ... the garment industry, PrettyTailor.com brings together art and technology ... The business carries quite a few in eye-catching patterns ...
(Date:11/28/2014)... The month of December has the highest ... occurring in Florida every year in December , attorney Sean ... insurance policies. , "Optional auto insurance coverage is something you ... cheap I know, actually Florida is among the states, where ... but what I see is that the insurance required by ...
(Date:11/28/2014)... News) -- People with diabetes face a number of challenges ... healthy, an expert says. "With the holidays coming, take ... events, the family you,ll be visiting and all of the ... Educators, said in an association news release. "By planning ahead. ... One idea is to make a healthy eating contract with ...
Breaking Medicine News(10 mins):Health News:BellasDress Offers A Big Surprise By Updating Its Cheap and Charming Cocktail Dresses 2Health News:New Access Control Systems Now Offered At Low Prices By Smartware Manufacturer SWAccessControl.com 2Health News:2015 Wedding Dresses from PrettyTailor.com Available Now 2Health News:Car Accident Attorney Sean M. Cleary on Auto Insurance Policies Essential for Florida Drivers 2Health News:Holiday Eating Tips for People With Diabetes 2
... sedimentation rate (ESR) increases during pregnancy. Also, both ... ,The erythrocyte sedimentation rate is one of ... is helpful in detecting the presence of inflammation ... by anaemia, which may be present in inflammatory ...
... to be in critical condition in a hospital here where ... government said. // ,Narayanan, who turned 85 ... and Referral Hospital two days later and has been on ... his condition. He continues to be critical, the aide said. ...
... are now produced which has been found to have ... Immunotherapy vaccines. //Antibodies against the allergen is given as ... allergen or infection these antibodies which are already present ... ,Conventional antibody injections against allergy diseases such ...
... the November issue of the Journal of the National Cancer ... after treatment, and patients treated with the higher chemotherapy dose ... ,Germ-cell testicular cancer is the most common cancer among 20-40 ... an age at which they are starting a family, and ...
... is a FDA approved long-term treatment regime for patients ... therapy is now being offered to patients at NewYork-Presbyterian ... now the first treatment specifically approved for TRD in ... therapy has been unsuccessful atleast in four or more ...
... cancer does not mean that you can cool your heels, ... experts have warned people. // ,These warnings were ... by eminent doctors who took part in a panel discussion ... In a keynote address delivered on the occasion, Prof D ...
Cached Medicine News:Health News:Oral Edible vaccine for Allergy Vaccines 2Health News:Decline in Paternity Rates Following Treatment for Testicular Cancer 2Health News:FDA Approved Nerve-Stimulation Therapy Now Available In New York 2
... Infinity Triglycerides powder reagent once reconstituted ... of single liquid stability to help ... and provide quick result turnaround time. ... Triglycerides powder reagent provides a long ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The patented ... provides a long shelf life that ...
... Infinity Creatinine single liquid stable reagent ... of single liquid stability to help ... and provide quick result turnaround time. ... Creatinine reagent provides a long shelf ...
... Amylase powder reagent once reconstituted offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... powder reagent provides a long shelf ...
Medicine Products: